Gene Modified T Cell Therapy for CLL
In a cancer treatment breakthrough 20 years in the making, researchers from Penn's Abramson Cancer Center and Perelman School of Medicine demonstrated sustained remissions of up to a year among a small group of patients with advanced chronic lymphocytic leukemia (CLL) treated with genetically engineered versions of their own T cells.
The Car T Cell Trial is a clinical trial that involves removing the patients' cells and modifying them in Penn's vaccine production facility in Philadelphia. Those cells are then infused the back into the patients following chemotherapy, providing a tumor-attack roadmap for the treatment of other cancers including those of the lung and ovaries and myeloma and melanoma.
Breast Cancer Vaccine Trial
The personalized vaccine, made partly from a patient's own white blood cells, is being used in this early breast cancer trial in an effort to teach the immune system to stand guard against a cancer recurrence. Brian J. Czerniecki, MD, PhD, Rhoads-Harrington Associate Professor of Surgery and Surgical Director, Rena Rowan Breast Center and the Abramson Cancer Center's Immunotherapy, is leading this first-ever DCIS vaccine study.